LDL

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May

Retrieved on: 
Wednesday, April 10, 2024
Cholecalciferol, LDL, CRM, Cholesterol, Cardiovascular disease, Medicine, Digital, Dietary supplement, Business, Risk, Patient, Pharmacy, DSM-IV codes, ERP, Research, Stroke, Pharmacist, Business development, Executive Committee, HEART, Artery, Research and development, Omega-3 fatty acid, Safety, Enterocyte, Lipid metabolism, General practitioner, Marketing, Practitioner, Sleep, Hypercholesterolemia, Pharmaceutical industry

The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."

Key Points: 
  • The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."
  • Available behind the counter in pharmacies, the dietary supplement will also be sold without a prescription with a pharmacist’s recommendation.
  • It comprises a new generation of dietary supplements with active ingredients of natural origin, acting on several targets for comprehensive management.
  • A principal mechanism controls intestinal cholesterol absorption, while a complementary mechanism acts on hepatic metabolism for a comprehensive approach to the management of hypercholesterolemia.

Beyond Meat® Unveils New and Expanded Line of Beyond Crumbles, Now Certified by the American Heart Association’s Heart-Check Program and the American Diabetes Association’s Better Choices for Life Program

Retrieved on: 
Thursday, March 28, 2024
American Heart Association, Health, LDL, Certification, Cardiovascular disease, Taste, BYND, Nutrition, TMAO, Nutrient, Diabetes, American Journal, American Cancer Society, Stroke, Crumble, Beyond Meat, Sodium, Food, Death, Risk, Breakfast, Diet, American Diabetes Association, Beyond, Reference Daily Intake, Lunch, Cholesterol, American Heart, Dietary supplement

Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.

Key Points: 
  • Convenient and easy to prepare, simply sauté the crumbles for four minutes in a skillet before adding them to your favorite dish or sauce.
  • Beyond Crumbles’ strong nutritional profile, coupled with its simple and clean ingredient list, earned the product certification by the American Heart Association’s Heart-Check program and the American Diabetes Association’s Better Choices for Life program,” said Beyond Meat Founder and CEO Ethan Brown.
  • As part of Beyond Meat’s commitment to innovating for human health, this announcement follows Beyond Steak’s earlier certifications by the American Heart Association and the American Diabetes Association .
  • With 1.2 million Americans diagnosed with diabetes every year , the Better Choices for Life Program uses the American Diabetes Association’s evidence-based guidelines to help consumers make informed choices about the foods they purchase.

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Blood pressure, Body composition, LDL, Adipose tissue, Obesity, Development, Cirrhosis, Three Months, Exercise, Arrhythmia, Hepatitis B virus, Diabetes, Lipid, Patient, Heart rate, Fast Track, Weight loss, Sarcopenia, MASH, Woman, Diet, Investment, Fibrosis, Safety, Optimism, FDA, Triglyceride, IMPACT, Dietary supplement

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

New Clinical Study Reveals Consuming 12 Eggland's Best Eggs Weekly Shows No Negative Effects on Cholesterol Levels; Study Also Suggests Possible Benefits for Some Consumers

Retrieved on: 
Monday, April 8, 2024
Research, Health, LDL, Cardiovascular disease, Vitamin, Nutrient, Cardiology, Diabetes, Risk, Patient, Senior, American College, Clinical trial, HDL, Cholesterol, Egg as food, Duke, Vitamin B12, Pharmaceutical industry

CEDAR KNOLLS, N.J., April 8, 2024 /PRNewswire/ -- Americans are increasingly aware of the impact of cholesterol on heart health and well-being, but for decades, there have been conflicting headlines about which foods can have positive or negative effects. Eggs, in particular, have often received negative press related to cholesterol. However, a new study presented at the American College of Cardiology's Annual Scientific Session that was led by researchers at Duke and sponsored by Eggland's Best, offers promising new evidence on fortified eggs.

Key Points: 
  • The clinical trial studied 140 participants from a broadly generalized population who had a high risk of heart disease.
  • Researchers randomized participants into two groups, asking half to eat two or fewer eggs per week for four months.
  • Ultimately, the study found that over 4 months, eating Eggland's Best eggs resulted in no adverse effects on lipid profiles and markers of cardiovascular risk for these patients.
  • The consumption of Eggland's Best eggs may also increase Vitamin B12 levels, also helping to support a healthier lifestyle.

Immunovant Awarded U.S. Patent for IMVT-1402

Retrieved on: 
Tuesday, March 12, 2024
Neonatal Fc receptor, LDL, Immunoglobulin G, Serum albumin, Patent, Autoimmune disease

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

Key Points: 
  • NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.
  • 11,926,669 (“the ‘669 patent”) for IMVT-1402, the Company’s second-generation antibody targeting the neonatal fragment crystallizable receptor (FcRn).
  • Not including any potential patent term extension, the ‘669 patent will expire on June 23, 2043.
  • IMVT-1402 is being developed by Immunovant based on antibody discovery efforts by HanAll Biopharma.

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
Wednesday, April 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
Tuesday, March 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

Retrieved on: 
Friday, February 23, 2024
Litre, Arrangement, Health Canada, OBG, TSX, Data monitoring committee, LDL, MBA, Assay, Safety, Cheese, University, Food engineering, University of Alberta, CZO, Infant, NPN, Journal, Protein, Clinical trial, Whey, Canada Business Corporations Act, Tissue, Water, Dietary supplement

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Key Points: 
  • EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
  • In addition to the proposed Arrangement, the Company continues to execute on progress across its ongoing development projects, as detailed below.
  • “We continue to make promising progress across all areas of our business.
  • Given the recent developments, we anticipate that all key success factors will align to expand our business model.

Lining Division Ltd. Receives ISO 9001:2015 Certification for Quality Management

Retrieved on: 
Thursday, February 29, 2024
ISO, Certification, CIPP, Record, LDL, Documentation, NDC, Management

BEXHILL ON SEA, England, Feb. 29, 2024 /PRNewswire/ -- Lining Division Ltd. (LDL), a division of the Vortex Companies (Vortex) and a leading UK-based installer of CIPP liners, pressure liners for sewer rising mains, infiltration control, and geopolymer mortar for structural manhole and chamber rehabilitation, today announced it has achieved ISO 9001:2015 Certification for its quality management system.

Key Points: 
  • "LDL works hard to ensure a high standard of product and service on every wastewater rehabilitation project," said Mike Vellano, CEO of Vortex.
  • "Our receipt of the ISO 9001:2015 certification codifies our commitment to quality in every aspect of business operations and infrastructure maintenance and provides a new level of confidence for customers."
  • The certification was issued after discussions with top management, a sampling of processes, and a review of associated documentation and records by NDC Certification Services, Ltd., an independent assessor.
  • "We couldn't be prouder of our quality management system and what we will achieve in the future.